spacer
home > ebr > summer 2018 > driving discovery
PUBLICATIONS
European Biopharmaceutical Review

Driving Discovery

EBR: What are the benefits of mass spectrometry (MS) as an analytical method?

Simon Cubbon: MS, from its early beginnings through to its current use, has seen an ever-increasing adoption; this is because of the large amounts of information, resulting in quality and, therefore, confidence that this technique can provide, ultimately, safeguarding end-users.

Additionally, both high- and low-resolution systems are becoming increasingly simpler to use; this, combined with the intricacy of products being brought to market (eg protein-based therapeutics, such as monoclonal antibodies or antibodydrug conjugates), requires techniques that can provide the necessary structural insights needed to fully characterise and understand these complexities.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Simon Cubbon works as a pharma and biopharmaceutical Vertical Marketing Manager at Thermo Fisher Scientific. He has worked within the analytical instruments industry for over 10 years, holding a variety of positions from applications scientist through to informatics product management. Simon studied for his PhD at the University of York, UK, where he was interested in using LC-MS to study the metabolic profile of long bone fractures.
spacer
Dr Simon Cubbon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Drive for generics sees Korea increasingly attractive to international pharma

Amsterdam, 31st July 2019: Already home to more than 40 pharmaceutical multinationals, Korea is on course to become a global biotech and pharmaceutical hub by 2025, driven by the surge of international partnerships, biosimilars, an expansion in the export of finished formulations and a robust generics market.
More info >>

White Papers

Running Better Trials Taking an Intelligent Monitoring Approach

Bioclinica

When it comes to implementing a risk-based monitoring program, it is not just about reducing monitoring visits and doing less Source Document Verification (SDV). Itís about bringing together your people, a solid process, and the right technology to run a better trial. Success with risk-based monitoring requires the ability to make sense of the thousands, if not millions, of data points captured by multiple disparate sources in a clinical trial. With the sheer volume of data generated on a daily basis comes complexity. How does one make sense of it all? Information overload burdens even the most experienced study teams who struggle to understand which data matters most and what it means.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement